To include your compound in the COVID-19 Resource Center, submit it here.

Pirenzepine: Development discontinued

AC Immune discontinued development of ACI-91 after top-line data from a double-blind, placebo-controlled, German and Austrian Phase II trial in 63 patients with mild to

Read the full 250 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE